yourstate.us
21 U.S.C. § 353c

Prereview of television advertisements

United States · Title 21 — FOOD AND DRUGS · Status: effective

Get this as JSONEmbed this
Cite this
Citation
21 U.S.C. § 353c, Prereview of television advertisements, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/454229
Permanent ID
ys:prov:454229@1
SHA-256
08f43f6cb593fd37f405fb4b5c1048ab5beeacb881ec7e17e72102dfcf80e9f4

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

The Secretary may require the submission of any television advertisement for a drug (including any script, story board, rough, or a completed video production of the television advertisement) to the Secretary for review under this section not later than 45 days before dissemination of the television advertisement. In conducting a review of a television advertisement under this section, the Secretary may make recommendations with respect to information included in the label of the drug— on changes that are— Except as provided by subsection (e), this section does not authorize the Secretary to make or direct changes in any material submitted pursuant to subsection (a). In formulating recommendations under subsection (b), the Secretary shall take into consideration the impact of the advertised drug on elderly populations, children, and racially and ethnically diverse communities. In conducting a review of a television advertisement under this section, if the Secretary determines that the advertisement would be false or misleading without a specific disclosure about a serious risk listed in the labeling of the drug involved, the Secretary may require inclusion of such disclosure in the advertisement. In conducting a review of a television advertisement under this section, the Secretary may require the advertisement to include, for a period not to exceed 2 years from the date of the approval of the drug under section 355 of this title or section 262 of title 42, a specific disclosure of such date of approval if the Secretary determines that the advertisement would otherwise be false or misleading. Nothing in this section may be construed as having any effect on requirements under section 352(n) of this title or on the authority of the Secretary under section 314.550, 314.640, 601.45, or 601.94 of title 21, Code of Federal Regulations (or successor regulations).

Legislative history

The public laws that enacted or amended this section. Tallies are for the whole bill as it passed each chamber — often an omnibus covering far more than this provision — not a vote on this section alone.

  • Enacted byPub. L. 110-85(H.R. 3580)2007-09-27
    Food and Drug Administration Amendments Act of 2007
    House: 405–7Senate: no recorded tally
  • Amended byPub. L. 113-54(H.R. 3204)2013-11-27
    Drug Quality and Security Act
    House: no recorded tallySenate: no recorded tally